Hear from us 6 July 2022 OCTALFA announces the inclusion of the first patient in the French Early Access Program granted to its subsidiary ORPHELIA Pharma for the use of KIMOZO® 40 mg/ml (temozolomide oral suspension) in the treatment of relapsed or refractory neuroblastoma Read More 9 June 2022 ORPHELIA Pharma and Gustave Roussy announce the publication in Pharmaceuticals of the scientific work related to the development of the first temozolomide oral suspension for children Read More 31 May 2022 ORPHELIA reports positive results of the bioequivalence study of KIMOZO® (oral suspension of temozolomide) Read More 11 May 2022 ORPHELIA Pharma has been awarded a € 1 million grant from Bpifrance to develop a therapy for a rare form of epilepsy Read More 15 February 2022 International Childhood Cancer Day Read More 4 February 2022 World Cancer Day Read More « Précédente1234567Suivant »
